These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8213589)

  • 1. The rapid reduction in cardiac events with lipid-lowering therapy: mechanisms and implications.
    Pearson TA; Marx HJ
    Am J Cardiol; 1993 Nov; 72(14):1072-3. PubMed ID: 8213589
    [No Abstract]   [Full Text] [Related]  

  • 2. Lipid-lowering therapy and risk of coronary events.
    Blakely JA
    JAMA; 2003 Apr 23-30; 289(16):2070-1; author reply 2071-2. PubMed ID: 12709461
    [No Abstract]   [Full Text] [Related]  

  • 3. Lipid-lowering therapy and risk of coronary events.
    Mascitelli L; Pezzetta F
    JAMA; 2003 Apr 23-30; 289(16):2071; author reply 2071-2. PubMed ID: 12709464
    [No Abstract]   [Full Text] [Related]  

  • 4. Lipid-lowering therapy and risk of coronary events.
    Taylor WC
    JAMA; 2003 Apr 23-30; 289(16):2070; author reply 2071-2. PubMed ID: 12709462
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients.
    Am J Cardiol; 1993 Nov; 72(14):1031-7. PubMed ID: 8213583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do statins have a specific drug effect beyond low-density lipoprotein-cholesterol-lowering in the secondary prevention of coronary artery disease?
    Dohi T
    Circ J; 2015; 79(1):49-50. PubMed ID: 25476194
    [No Abstract]   [Full Text] [Related]  

  • 7. [Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly].
    MMW Fortschr Med; 2005 Aug; 147(33-34):50-1. PubMed ID: 16138640
    [No Abstract]   [Full Text] [Related]  

  • 8. The MEGA study.
    Nango E; Saio T; Yuasa H
    Lancet; 2006 Dec; 368(9552):2051; author reply 2052. PubMed ID: 17161723
    [No Abstract]   [Full Text] [Related]  

  • 9. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pravastatin in patients with cardiac risk factors. Effects of pravastatin in patients with total serum cholesterol concentrations of 200 to 300 mg/dl (5.2 to 7.8 mmol/l) and two additional atherosclerosis risk factors. Pravastatin Multinational Study Group for Cardiac Risk Patients].
    Fortschr Med; 1994 Feb; 112(5):57-64. PubMed ID: 8163252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
    Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
    Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical study of the month. The ALLHAT-LLT trial].
    Kulbertus H; Scheen AJ
    Rev Med Liege; 2003 Jan; 58(1):53-8. PubMed ID: 12647600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial.
    Uchiyama S; Nakaya N; Mizuno K; Ohashi Y; Tajima N; Kushiro T; Teramoto T; Nakamura H;
    J Neurol Sci; 2009 Sep; 284(1-2):72-6. PubMed ID: 19423132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.
    Keech A; Colquhoun D; Best J; Kirby A; Simes RJ; Hunt D; Hague W; Beller E; Arulchelvam M; Baker J; Tonkin A;
    Diabetes Care; 2003 Oct; 26(10):2713-21. PubMed ID: 14514569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of high-density lipoprotein cholesterol control during pravastatin treatment in hypercholesterolemic Japanese with type 2 diabetes mellitus: a post hoc analysis of MEGA study.
    Nishimura R; Sone H; Nakagami T; Tajima N
    Diabetes Res Clin Pract; 2013 May; 100(2):e31-3. PubMed ID: 23522341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
    Tonelli M; Isles C; Curhan GC; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; Craven T; West M
    Circulation; 2004 Sep; 110(12):1557-63. PubMed ID: 15364796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol lowering with statins: how WOSCOPS confounded the skeptics.
    Shepherd J
    Atheroscler Suppl; 2007 Aug; 8(2):9-12. PubMed ID: 17586101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bridging the treatment gap.
    Smith SC
    Am J Cardiol; 2000 Jun; 85(12A):3E-7E. PubMed ID: 10858487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pravastatin, a new cholesterol synthesis inhibitor for lowering increased serum cholesterol].
    Hoppichler F; Lechleitner M; Patsch JR
    Z Gesamte Inn Med; 1992 Nov; 47(11):523-7. PubMed ID: 1462678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin.
    Nakamura H;
    Atheroscler Suppl; 2007 Aug; 8(2):13-7. PubMed ID: 17586102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.